MEDIPOST enters an agreement with LG Chem to transfer its MLSC technology, a next-generation cell culture platform technology, to develop gene and cell therapy products
MEDIPOST starts cord blood-derived immune cell therapy development with the establishment of its subsidiary “IMMUNIQUE”
MEDIPOST enters into new business and accelerates its clinical trials in the U.S. through third-party allotment financing
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billion, to be Used for Global Market Expansion Including the U.S.
